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Vertical suppression of the EGFR pathway prevents
onset of resistance in colorectal cancers
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Molecular targeted drugs are clinically effective anti-cancer therapies. However, tumours
treated with single agents usually develop resistance. Here we use colorectal cancer (CRC) as
a model to study how the acquisition of resistance to EGFR-targeted therapies can be
restrained. Pathway-oriented genetic screens reveal that CRC cells escape from EGFR
blockade by downstream activation of RAS-MEK signalling. Following treatment of CRC cells
with anti-EGFR, anti-MEK or the combination of the two drugs, we find that EGFR blockade
alone triggers acquired resistance in weeks, while combinatorial treatment does not induce
resistance. In patient-derived xenografts, EGFR-MEK combination prevents the development
of resistance. We employ mathematical modelling to provide a quantitative understanding of
the dynamics of response and resistance to these single and combination therapies.
Mechanistically, we find that the EGFR-MEK Combo blockade triggers Bcl-2 and Mcl-1
downregulation and initiates apoptosis. These results provide the rationale for clinical trials
aimed at preventing rather than intercepting resistance.
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T
he evidence that cancer is a malady of genes has
revolutionized diagnosis and treatment of this disease1,2.
A central paradigm of modern oncology is that tumour-
specific molecular alterations (such as HER2 amplification or
EGFR and BRAF mutations) underlie ‘functional’ dependencies
that can be therapeutically exploited3. Remarkable results
have been obtained by applying this paradigm in the clinic and
several ‘targeted’ drugs were approved to treat, among others,
melanomas, lung and colorectal cancers (CRCs). When ‘targeted’
agents were employed in the clinic it quickly became apparent
that patients treated with single agents almost always develop
resistance within months after initiating therapy4–9.
A typical observation is that after an initial regression all the
metastatic lesions reappear, virtually simultaneously10. How can
we overcome the near-certainty of disease recurrence following
treatment with targeted agents? If resistance is directly dependent
on the number of cells that are treated, in principle, the
best options would be to treat tumours when they are very
small, before a sufficient number of mutant cells conferring
resistance have accumulated. Unfortunately, this option is
presently unfeasible as most tumours are discovered when
cancerous lesions already contain billion of cells. Another
feature, which limits the efficacy of targeted agents, is molecular
heterogeneity. Solid tumours typically display high levels
of genomic instability, which fuels the perpetual generation of
molecular diversity. As a consequence, therapeutic challenges
result in selection of sub-clonal cell populations, capable of
growing under drug pressures11.
A possible approach to overcome the limitations of targeted
agents is to use combinations rather than mono-therapies. This
involves treating tumours with two or more agents that hit
different targets, as this should reduce the chance of having cells
resistant to both drugs12. Combination therapy is supported by
the success of pharmacological combinations for systemic
infectious diseases such as HIV13. In oncology, experimental
evidence that combinations of targeted agents confer advantages
over sequential treatments arise from melanoma patients treated
concomitantly with anti-BRAF and anti-MEK drugs14.
In this work, we studied CRC as a model system to assess how
the emergence of resistance to targeted therapies can be
delayed or prevented. The anti-epidermal growth factor receptor
(EGFR) antibodies cetuximab and panitumumab are used
to treat metastatic CRCs lacking RAS pathway mutations4,15.
Unfortunately, CRC patients who respond to EGFR antibodies
almost invariably develop resistance within several months of
initiating therapy16,17. Currently, there are no effective ways to
control the onset of acquired resistance to EGFR blockade. We
reasoned that it may be preferable to prevent the emergence of
resistance rather than targeting tumour cells that had already
acquired resistance. Functional genetic screening and pharma-
cological approaches demonstrated a strong dependency from
EGFR-MEK pathway, which we exploited as a combinatorial
treatment (EGFR plus MEK inhibition) on CRC cells and
xenopatients. Our results demonstrate that EGFR-MEK double
blockade limits the emergence of resistant clones preventing
secondary resistance by inducing apoptosis more effectively then
single agents alone. Mathematical modelling allowed quantitative
understanding of the dynamics of response and resistance to
mono and combination therapies.
Results
MAPK pathway activation drives resistance to EGFR blockade.
To identify signalling pathways with the potential to confer
resistance to anti-EGFR antibodies, we performed a functional
genetic screen. Two CRC cell models (DiFi and CCK81) sensitive
to EGFR blockade were infected with a library of 27 pathway-
activating mutant cDNAs (Supplementary Table 1). For most
signalling pathways, multiple Open Reading Frames (ORFs) were
included that on ectopic expression, rendered the pathway con-
stitutively active. Each construct was individually barcoded thus
allowing sequence-based screen, and most constructs were func-
tionally validated to ensure constitutive activation of their cognate
pathways in cells18. Constitutive activation of RAS-MAPK
signalling (but not of other pathways) was sufficient to confer
resistance to EGFR blockade (Fig. 1a,b). Comparable results were
obtained with two independent CRC cell lines (Supplementary
Fig. 1).
Dual blockade of EGFR and MEK prevents acquired resistance.
If MAPK activation is necessary to sustain resistance to
EGFR blockade, we reasoned that vertical suppression of EGFR
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Figure 1 | The RAS-MAPK pathway drives resistance to EGFR blockade
in CRC cells. CCK81 (a) and DiFi (b) cells were infected with pathway
specific cDNAs and treated with panitumumab. GI50 values are reported in
logarithmic scale. Data are representative of three biological replicates and
error bars represent s.d. Details on the constructs are listed in
Supplementary Table 1.
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signalling by concomitant EGFR-MEK targeting could delay or
prevent the emergence of resistant clones. To experimentally
verify the hypothesis we devised a cell-based test that parallels
time to progression (TTP), a parameter commonly used in
the clinic. In cancer patients, TTP is defined as the time from the
start of treatment until disease worsens or spreads to other parts
of the body because of tumour growth. The in vitro TTP assay
defines the emergence of acquired resistance as the time at
which a fixed number of cells start to grow in an exponential
manner in the presence of drug(s). We found that in the
presence of cetuximab, time to resistance depends on the
initial cell input (Supplementary Fig. 2). An increased number of
input cells correlated with a shorted TTP, consistent with the
hypothesis that cells resistant to EGFR blockade are pre-existing17
(Supplementary Fig. 2).
In DiFi and CCK81, the TTP assay shows that inhibition of
MEK alone had modest or no impact. We further found that
resistance to cetuximab occurs within 80–120 days after therapy
initiation depending on the cell line. Similar results were obtained
in multiple CRC cell models (Fig. 2).
We next asked what would happen if the EGFR-MEK combo
treatment was applied to population of cells at the time they
developed acquired resistance to cetuximab. Some of the
cetuximab-resistant models displayed sensitivity to the EGFR-
MEK therapy (CCK81 and C99) while others, after a short-lived
growth inhibition, quickly evaded combinatorial treatment (Fig. 2).
Most notably, concomitant suppression of EGFR and MEK in
treatment-naive cells had a remarkable effect, as we were unable to
detect emergence of resistant clones up to 6 months after initiation
of treatment (Fig. 2). Of note, we found that high dose mono-
agents are not cytotoxic (Supplementary Fig. 3).
Combinatorial therapy prevents resistance in CRC PDX. To
assess more directly the clinical relevance of our findings we
employed a patient-derived xenograft (PDX or xenopatient)
sensitive to EGFR blockade. This was derived from an individual
carrying a quadruple wild-type (KRAS, NRAS, BRAF and
PIK3CA) colorectal tumour, and thus recapitulates the molecular
profile of patients sensitive to anti-EGFR antibodies. To measure
the TTP in vivo, the xenograft was first expanded in four cohorts
that were treated for 6 weeks with vehicle, cetuximab, the MEK
inhibitor pimasertib or the combination. As observed in vitro,
MEK blockade had a marginal effect on tumour growth while
cetuximab and combinatorial treatments significantly reduced
tumour size in all animals. By week 7 tumours treated with
cetuximab had shrunk by 70% but were still palpable; on the
contrary those who received EGFR-MEK combo blockade were
undetectable (Fig. 3a,b and Supplementary Data 1). To assess
whether treatments had been curative, at week 9 both regimens
were suspended while tumour sizes continued to be monitored.
Tumours that had previously received only cetuximab immedi-
ately begun to regrow while those that had been treated with
EGFR and MEK inhibitors remained undetectable or showed
marginal growth by week 15 (Fig. 3a,b and Supplementary
Data 1). At this point both drug schedules were restarted.
Tumours that previously received cetuximab alone momentarily
halted their expansion on drug re-challenge and then swiftly
resumed growth. On the contrary, those tumours treated with the
combo regimen remained undetectable until week 28.
To further validate the in vivo results, we repeated the
experiment with the PDX avoiding treatment interruption.
This second replicate, confirmed the results obtained in the first
experiment, emphasizing the finding that combinatorial treat-
ment allow complete xeno-tumour remission (Supplementary
Fig. 4a and Supplementary Data 2).
The same experimental strategy was then applied to an
independent PDX that was also derived from a quadruple wild-
type (KRAS, NRAS, BRAF and PIK3CA) colorectal tumour and
was sensitive to EGFR blockade. Analogously to what we
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Figure 2 | Concomitant blockade of EGFR and MEK halts the emergence of resistance in CRC cell lines. CCK81 (a), DiFi (b), C99 (c), NCIH508
(d) and HCA-46 (e). Cell lines were seeded at 20 million (CCK81 and C99) and 10 million (DiFi, NCIH508 and HCA-46) cell density and treated with
cetuximab alone (340nM), pimasertib alone (250 nM) and with the combination of the two drugs from day 0 or at the time of acquired resistance
to cetuximab. Cells were detached and counted at least once a week as described in Methods section. A single biological replicate is represented for each
cell model. Non-linear fit with exponential growth curve (Graphpad Prism) was applied to data points to show growth kinetics.
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observed in the first xenopatient the effect of monotherapy with
cetuximab was transient and secondary resistance developed at
week 16 of treatment (Supplementary Fig. 4b–c). On the contrary
secondary resistance was not detected in the combo treated
arm until week 23 when the experiment was terminated
(Supplementary Fig. 4b–c and Supplementary Data 3).
Mathematical modelling of drug resistance in PDX. It has been
postulated that the limited efficacy of therapies based on single
agents is related to the presence of drug-resistant cells at the start
of treatment12,17,19–24. We reasoned that the xenopatients’ data
could offer a unique opportunity to study the size of this resistant
subpopulation and quantify the dynamics of CRC treated with
mono or combo therapies. To this end, we used mathematical
modelling to analyse the experimental data. We started by fitting
the average volume of tumours from the replicate experiment
treated with cetuximab (Supplementary Data 2) to a cancer
dynamics model, which assumes that tumours contain a mix of
sensitive and resistant cells at the time of treatment initiation
(Supplementary Methods):
V tð Þ¼a exp btð Þþ c exp dtð Þ ð1Þ
Here a is the volume of sensitive cells in the tumour at time 0
(start of treatment) and bo0 is their (fixed) net growth rate
during treatment. c is the volume of resistant cells at day 0 and
d40 is their (fixed) net growth rate during treatment. The model
assumes deterministic exponential growth and independence of
sensitive and resistant clones, and further assumes that drugs
have constant effect on cells throughout the duration of
treatment. This simple model fits the data well (R2¼ 0.97,
Fig. 4a) without the need to invoke additional assumptions. As
described in the Supplementary Methods the assumptions of
exponential growth and independence of clones become violated
in large tumours (with volumes larger than B1,000mm3) when
growth slows down and turns from exponential to logistic
(Supplementary Fig. 5a,b).
The best fit to cetuximab-treated xenopatient data was
obtained with a model in which the volume of resistant cells at
the start of treatment is c¼ 8.8 (95% CI, 2.8–14.8) mm3 and the
volume of sensitive cells is a¼ 417.2(95% CI, 365–469.5) mm3.
In other words, B2% of all cells present in the tumour at the
start of treatment are resistant to cetuximab and they grow
during treatment at rate d¼ 0.038(95% CI, 0.031–0.045) per day.
Sensitive cells decline at rate b¼ 0.062(95% CI,  0.077 to
 0.046) per day during treatment (Supplementary Table 2).
The original xenopatient experiment included cessation of
treatment, and, by fitting these data to a more complicated
mathematical model that included four phases of treatment and
its absence (Supplementary Methods and Supplementary Fig. 5c),
we found that the growth rate of resistant cells in the absence of
treatment was e¼ 0.028 (95% CI, 0.017–0.038) per day, while the
growth rate of sensitive cells in the absence of treatment was
f¼ 0.078 (95% CI, 0.041–0.12) per day. This means that
resistance is costly in the absence of treatment as it decreases
the net growth rate by B0.05 per day. The relatively high
percentage of resistant cells at the start of treatment in spite of the
cost of resistance can be explained by a relatively high rate of
production of resistant cells from the sensitive population before
treatment. It can be shown that disadvantageous cells that are
produced with rate u, and which decrease the net growth rate by a
cost z, are present in the population at an average fraction of u/z
(mutation-selection balance). It follows that the rate of
production of resistant cells is on the order of 0.001 per day.
This rate is much higher than if resistance was mediated byB100
point mutations, when it would be B10–7, indicating that the
mechanism of resistance is not mediated by point mutations only,
but likely via other genetic or non-genetic mechanisms.
In the case of EGFR-MEK combinatorial treatment, we see no
evidence of resistant cells in tumour volume data, and thus we fit
a model that contains only sensitive cells. The model assumes that
sensitive cells decline with rate bo0 during treatment (Supple-
mentary Methods and Supplementary Table 3):
V tð Þ ¼ a exp btð Þ: ð2Þ
Volume of sensitive cells at the start of therapy (day 0) is a. Again
this model fits the xenopatient data well (R2¼ 0.99; Fig. 4b).
We find that sensitive cells decline with rate b¼  0.096
( 0.10,  0.088) during combinatorial treatment. These results
suggest that there were still approximately a million sensitive cells
in the tumour when the treatment in the original experiment was
stopped and these sensitive cells grew back in the absence of
treatment (Fig. 3a, Supplementary Fig. 5d). In addition, fitting
the tumour volume data from the original experiment with
combinatorial treatment, we find that cells sensitive to
combination treatment grow slower after being exposed to the
treatment compared with untreated sensitive cells. The
growth rate of combination-treated cells in the absence of
therapy is 0.05 (95% CI 0.037–0.062) per day versus 0.085 (95%
CI 0.074–0.096) per day for untreated cells. For consistency, we
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Figure 3 | Vertical blockade of the EGFR pathway prevents the emergence of resistance in PDX. A cetuximab sensitive CRC PDX (xenopatient) was
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also applied our model to the second PDX (Supplementary
Methods, Supplementary Fig. 5e,f and Supplementary Table 4).
Given these results, there is no evidence in xenograft
experiments of the existence of dual-resistant cells. To better
understand this, we performed immunohystochemical analyses
on tumour sections derived from the first PDX model. Using this
approach we were able to determine that the tumour ‘scar’, which
is present at the end of the experiment in the combo treated mice
corresponds essentially to necrotic tissue. Even when a few
tumour cells appear to be still present, they are not proliferating
as shown by Ki67 staining (Fig. 5). Taking into account the last
non-zero volume measurement (13.5mm3 or B13.5 million
cells) of the tumour from the mouse in which a small number of
non-proliferative tumour cells were found, the time from this
measurement to the end of the experiment (84 days) and the
estimated death rate of sensitive cells during combo treatment
( 0.096 per day), it is expected that B4,000 sensitive cells were
still present at the end of the experiment that have not yet been
killed by the treatment. Thus, we postulate that the small amount
of non-proliferative cells found in one of the combo treated mice
are likely sensitive cells that are not yet killed by the treatment
(Fig. 5). Total tumour volume in the four mice treated with the
combination is B1,600mm3 or B1.6 billion tumour cells. Since
none of the four mice treated with the combination harboured
any surviving cells resistant to the combo, we can conclude that
the frequency of pre-existing successful combo-resistant cells is
o1 in a billion. It is possible that each tumour contained a small
number of combo-resistant or persistor cells, which were not
sufficient to form a surviving resistant population, or that died
due to stochastic drift.
Mathematical modelling of drug resistance in cell models. Since
it was impossible to assess the fitness of cells resistant to com-
binatorial treatment from the xenopatient experiments, we turned
to in vitro experiments in which double EGFR-MEK-resistant
mutants appeared in a population that was already resistant to
cetuximab. We first fit the cell number data from a DiFi cell line
treated with cetuximab to the same model used for fitting
xenopatient tumours treated with cetuximab (equation 1). The
only difference is that now a and c are cell numbers and not
volumes. The fit of the model to the data was excellent
(R2¼ 0.999, Fig. 6a). Out of 10 million cells that were present at
the start of treatment, only c¼ 1,077 (95% CI, 240–1,915) were
resistant to cetuximab. These resistant cells expanded during
treatment at rate d¼ 0.114 (95% CI, 0.105–0.123) per day. Sen-
sitive cells were declining during treatment at rate b¼  0.165
(95% CI,  0.217 to 0.113) per day. Ten million cells that
developed resistance to cetuximab were plated and treated with
combination of cetuximab and pimasertib. The same model (1)
was again an excellent fit to the cell number data (R2¼ 0.99;
Fig. 6b). Out of 10 million initial cells, c¼ 1.5  104 (95% CI, 550–
3 104) are predicted to have been resistant to the combination
at the start of treatment. Their growth rate during treatment was
d¼ 0.069 (95% CI, 0.060–0.078) per day, smaller compared with
the growth rate of cells resistant to cetuximab only. In summary,
B1 in 10,000 DiFi cells are resistant to cetuximab; out of
cetuximab-resistant cells, B1 in 1,000 are resistant to the combo
but they emerged only on the acquisition of cetuximab resistance.
Our modelling results show that the frequency of pre-existing
combo-resistant cells may vary in different cell lines and patient
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Figure 5 | Immunohystochemical analyses of PDX derived samples. Two
levels of magnification are presented to better appreciate sample size. (a)
Ki67 staining of one representative example of Vehicle, Pima and Cmab
treated mice and the entire combo treated mice from which we were able to
obtain tissue at the end of the experiment. Percentage of positivity: Vehicle
6%, Pima 24%, Cmab 8% and Combo 0%. (b) Hematoxylin/Eosin staining
of one representative example of Vehicle, Pima and Cmab treated mice and
the entire combo treated mice from which we were able to obtain tissue at
the end of the experiment. Only in mouse #5 a small amount of cancer cells
is detectable, the rest are composed only by necrotic tissue. Scale bars,
50mm (a, right panels), 100mm (a, lefts panel; and b, right panels) and
500mm (b, left panels).
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tumours. Thus, a typical metastatic lesion that contains about a
billion cells may not have a single combo-resistant cell or it may
contain a small number of combo-resistant cells. The small
number of combo-resistant cells may not be sufficient to form a
successful resistant population (due to, for example, stochastic
drift)12, and in fact we never see resistance to combination
therapy in our experiments when the EGFR-combo is applied on
naive cells (as front line therapy). In contrast, when single therapy
such as cetuximab is the first line of treatment, resistance
inevitably develops and this cetuximab-resistant subpopulation is
much more likely to harbour a combo-resistant mutant. In sum,
both theoretical predictions12 and our experiments strongly
favour combination of EGFR and MEK combo blockade as first
line treatment of CRC patients.
Adaptive escape from MEK inhibition in CRC cells. Experi-
ments in cells and tumourgrafts and mathematical models indi-
cate that combinatorial blockade of EGFR and MEK impairs the
emergence of resistant clones in vitro and in vivo. At first this
tactic may seem counter-intuitive. Why should it be necessary to
intercept two nodes in the same pathway? To shed light on the
remarkable efficacy of EGFR-MEK concomitant inhibition we
performed biochemical analyses. The experiments of Fig. 2
indicate that CRC cells sensitive to EGFR blockade are virtually
unaffected by MEK inhibition and quickly resume exponential
growth in the presence of MEK suppression. Biochemical pro-
filing of EGFR downstream pathways in DiFi and CCK81 cells
revealed that MEK inhibition induces EGFR and AKT activation
(p-Y1068 and p-S473) and is unable to switch off ERK phos-
phorylation, thus suggesting an adaptive escape from MEK
blockade (Fig. 7a,b and Supplementary Fig 7a,b).
Combinatorial therapy triggers apoptosis in CRC models.
Results from fitting xenopatients data suggest that the supremacy
of combination versus single drug treatments is twofold: the
combination is not opposed by pre-existing resistance and is more
effective in killing cancer cells as compared with cetuximab (net
death rate 0.96 (95% CI, 0.088–0.10) versus 0.62 (95% CI, 0.046–
0.077) per day). To test whether the combination is more effective
in triggering apoptosis than monotherapy, we challenged DiFi and
CCK81 cells with mono or combo treatments and monitored
indicators of programmed cell death. In both cell lines the pro-
portion of fragmented nuclei (Fig. 7c and Supplementary Fig. 7c)
and of cleaved caspases-3 (Fig. 7d and Supplementary Fig. 7d) was
higher in combo treated cells compared with the other conditions.
We further found that combinatorial treatment is capable of
inducing apoptosis by triggering a significant decrease of Bcl-2 and
Mcl-1 (ref. 25) expression (Fig. 7e and Supplementary Fig. 7e).
Additional analyses showed that downregulation is mediated by
protein degradation through enhanced ubiquitination of Mcl-1
and by transcriptional down modulation of Bcl-2 (Supplementary
Fig. 7 and Supplementary Fig. 8). Altogether, these data show that
EGFR-MEK combo treatment induces apoptosis at a rate that is
approximately twofold higher compared with cetuximab mono-
therapy (Fig. 6a,b), consistent with predictions from mathematical
modelling of the xenopatient data.
Discussion
Analysis of candidate genes in CRC patients’ samples previously
indicated that acquired resistance to EGFR blockade is associated
with the emergence of clones carrying oncogenic mutations in the
EGFR-RAS signalling axis16,17,26–29. Biochemical studies showed
that resistance to EGFR blockade is almost invariably accompanied
by activation (constitutive phosphorylation) of MEK and ERK29.
Through a genetic screen involving 27 pathway-activating proteins
we now provide unbiased functional and biochemical evidence that
constitutive activation of RAS-MAPK signalling (but not of other
pathways) is sufficient to confer resistance to EGFR blockade. The
multitude of evidences suggesting that escape routes from EGFR
blockade in CRC biochemically convergence on MAPK activation
provides several opportunities, which we exploited in this work.
Using an assay that recapitulates TTP in vitro and in vivo, we
find that vertical suppression of the EGFR signalling pathway
halts or prevents the onset of acquired resistance in CRC cell and
xenopatients. Perhaps not unexpectedly when the same ther-
apeutic regimen is applied once resistance to monotherapy has
already occurred, the efficacy of the EGFR-MEK combo is only
transient. These results provide support for ‘ab initio’ combina-
torial therapies, which conceivably, could restrain the develop-
ment of resistant tumours displaying high levels of molecular
heterogeneity.
Mathematical modelling was used to quantify the dynamics of
sensitive and resistant clones, showing that clones resistant to
combination are unlikely to exist before treatment. Our modelling
approach provides a framework for comparing and contrasting the
long-term effects of cancer therapies in vitro and in vivo. The
mathematical analysis was focused on pre-existing resistance, even
though other mechanisms of resistance might be involved, such as
resistance arising de novo during treatment. Several studies tried to
estimate the significance of pre-existing versus de novo resistance
to therapy in cancer and in viral infections, and often found that
resistance mainly arises before treatment16,17,19,21.
Of note, emergence of double resistant clones was observed
only when single agent resistant populations were allowed to
develop and then treated with the combo regimen. Acquisition of
resistance to combinatorial therapy could thus potentially be
enabled by genetic or non-genetic mechanisms and enhanced
during cetuximab treatment. It also may be influenced by
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stochastic drift12 or clonal interference30 as well as by the
presence of so called ‘persistor cells31. Further investigations are
needed to better understand the mechanistic basis of resistance to
combo EGFR-MEK blockade.
Biochemical analyses revealed that vertical suppression of the
EGFR-MEK signalling pathway triggers apoptosis at a higher
rate (approximately twofold), compared with cetuximab alone.
On the basis of these results we propose that CRC cells without
RAS pathway mutations do not survive in the absence of
continuous signals coordinated by EGFR and MEK. We postulate
that the inability to develop resistance in vitro and in vivo stems
from suppression of a central (essential) pathway in CRC cells
lacking KRAS mutations. In this regard, the vertical blockade
described here may be the biochemical equivalent of synthetic
lethality. We further imply that EGFR-MEK concomitant
inhibition likely suppresses the emergence of resistant clones by
subduing the population of molecularly heterogeneous cancer
cells32, which fuels the relative rapid recurrences observed after
treatments based on EGFR antibodies.
In summary our results highlight that integration of clinical
data with functional analyses of preclinical models can lead to
rational therapies aimed at delaying or halting the emergence of
drug resistance in cancer cells. Our data indicate that EGFR/MEK
combo blockade is better than upfront treatment with anti-EGFR
antibodies or to delivering a MEK inhibitor when resistance to
cetuximab or panitumumab has already developed. As several
EGFR and MEK inhibitors are approved or in advanced clinical
development (alone or in combination) our results provide
grounds for clinical trials aimed at preventing rather than
intercepting resistance.
Methods
Cell cultures. DiFi cells were cultured in F12 medium (Invitrogen) supplemented
with 10% fetal bovine serum (FBS); CCK81 cells were cultured in MEM medium
(Invitrogen) supplemented with 10% FBS. LIM1215 cells were cultured in RPMI-
1640 medium (Invitrogen) supplemented with 5% FBS and insulin (1 mgml 1).
CCK81 cell line was obtained from HSRRB, Japan. The DiFi cell line was a kind gift
from Dr J. Baselga in November 2004 (Oncology Department of Vall d’Hebron
University Hospital, Barcelona, Spain) and Dr V. Cerundolo in March 2010
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(Weatherall Institute of Molecular Medicine, University of Oxford, UK),
respectively. C99 cells were cultured in Iscove’s medium (Invitrogen) supplemented
with 10% FBS; NCIH508 cells were cultured in RPMI-1640 medium (Invitrogen)
supplemented with 10% FBS, and HCA-46 cells were cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10% FBS. The NCIH508
cell line was purchased from American Type Culture Collection (LGC Standards
S.r.l). CCK81 cell line was obtained from HSRRB, Japan. C99 and HCA-46 cell
lines were obtained from ECACC (distributed by Sigma-Aldrich Srl). The LIM1215
parental cell line have been described previously33 and was obtained from
Professor Robert Whitehead, Vanderbilt University, Nashville, with permission
from the Ludwig Institute for Cancer Research, Zurich, Switzerland. The identity of
each cell line was checked by Cell ID System and by Gene Print 10 System
(Promega), through short tandem repeats (STR) at 10 different loci (D5S818,
D13S317, D7S820, D16S539, D21S11, vWA, TH01, TPOX, CSF1PO and
amelogenin). Amplicons from multiplex PCRs were separated by capillary
electrophoresis (3730 DNA Analyzer, Applied Biosystems) and analysed using
GeneMapperID software from Life Technologies. Resulting cell line STR profiles
were cross-compared and matched with the available STR from ATC, ECCAC, and
CellBank Australia repositories online databases. All cell lines were tested and
resulted negative for mycoplasma contamination with Venor GeM Classic kit
(Minerva biolabs).
TTP assay. For the TTP long-term assay, 20 million CCK81 and C99, and 10
million DiFi, NCIH508 and HCA-46 cell lines were plated in their respective
growth media with half serum (5%) and treated with cetuximab (340 nM), pima-
sertib, (250 nM) or the combination of the two. Cells were counted every 4 days
(CCK81 day 10 to day 70) or every week (all the other time points and cell lines).
Count as 0 represent time points in which cells were too few and only medium and
drug refreshments were done.
Immunoblot analysis. Before biochemical analysis, all cells were grown in their
specific media supplemented with 5% FBS. Total cellular proteins were extracted by
solubilizing the cells in cold EB buffer (50mM Hepes pH 7.4, 150mM NaCl, 1%
Triton X-100, 10% glycerol, 5mM EDTA, 2mM EGTA; all reagents were from
Sigma-Aldrich, except for Triton X-100 from Fluka) in the presence of 1mM
sodium orthovanadate, 100mM sodium fluoride and a mixture of protease inhi-
bitors (pepstatin, leupeptin, aprotinin, STI and phenylmethylsulfonyl fluoride).
Extracts were clarified by centrifugation, and protein concentration was deter-
mined using BCA protein assay reagent kit (Thermo). Western blot detection was
performed with enhanced chemiluminescence system (GE Healthcare) and per-
oxidase conjugated secondary antibodies (Amersham). The following primary
antibodies were used for western blotting (all from Cell Signaling Technology,
except where indicated): anti-phospho-p44/42 ERK (thr202/tyr204); anti-p44/42
ERK; anti-phospho-MEK1/2 (Ser217/221), anti-MEK1/2; anti-phospho-AKT
(Ser473), anti-AKT, anti-EGFR (clone13G8, Enzo Life Sciences); anti-phospho-
EGFR (tyr1068); anti-actin and anti-vinculin (Sigma-Aldrich), anti-PUMA, anti-
Bid, anti-cleaved-caspase-3 (Cell Signaling Technology), anti-Mcl-1 (Santa Cruz
Biotechnology), anti-Bak, anti-Bcl-2, anti-Bim, anti-Noxa (EMD Millipore), and
anti-Bcl-XL (BD Biosciences). All the antibodies were diluted 1:1,000 except for
total EGFR which was diluted 1:100. Mcl-1 ubiquitination was analysed by probing
immunoprecipitated Mcl-1 in cells transfected with HA-tagged ubiquitin and
treated with drugs at 6 h after transfection as described34.
Apoptosis analysis. After drug treatment, adherent and floating cells were
collected and resuspended with PBS solution containing 3.7% formaldehyde, 0.5%
Nonidet P-40, and 10mgml 1 Hoechst 33258 (Invitrogen). Apoptosis was assessed
through microscopic visualization and counting of cells with condensed chromatin
and micronucleations. For each measurement, at least three independent
experiments and a minimum of 300 cells were analysed. Caspase activity was
measured using the SensoLyte Homogeneous AMC Caspase-3/7 Assay Kit
(Anaspec) according to the manufacturer’s instructions. Briefly, 5.0 104 DiFi or
CCK81 cells were seeded in each well of a 96-well plate. After treatment, cells were
incubated with the caspase substrate Ac-DEVD-AMC at room temperature for
40 min. Fluorescence was measured using a Wallac Victor 1420 Multilabel Counter
(PerkinElmer), and the data were presented as relative fluorescence units.
Real-Time PCR. Total RNA was isolated from 3.0 105 cells using Mini RNA
Isolation II Kit (Zymo Research) according to the manufacturer’s protocol. One
microgram of total RNA was used to generate cDNA using SuperScript II reverse
transcriptase (Invitrogen). Real-time RT–PCR was performed on a CFX96
Real-Time PCR system (Bio-Rad, Hercules, CA) with SYBR Green (Invitrogen).
Bcl-2 and Mcl-1 were analysed by RT–PCR using primer pairs 50-ATGTGTGTG
GAGAGCGTCAACC-30/50-TGAGCAGAGTCTTCAGAGACAG-30 and 50-ATGC
TTCGGAAACTGGACAT-30/50-TGGAAGAACTCCACAAACCCA-30 ,
respectively, as previously described34.
GI50 assays with pathway-activating library. For details on the cloning,
sequencing and functional validation of the library of pathway-activating lentiviral
cDNAs, refers to Martz et al.18, Science Signaling 2014. cDNA-expressing
lentiviruses were produced as previously described35 and used to infect cells at a
1:10–1:20 dilution in 6-well plates in the presence of 7.5 mgml 1 polybrene.
Following virus addition, plates were centrifuged at 1,200g for 1 h at 37 C.
Twenty-four hours after infection, puromycin (2 mgml 1) was added for selection
and cells were incubated for 48–72 h. Cells were then trypsinized, counted, and
seeded into 96-well plates at 1,000 cells/well. Twenty-four later, media or tenfold
serial dilutions of panitumumab (in media) were added to cells (1:1,000) to yield
final concentrations ranging from 680 nM to 0.000068 nM. The Cell Titer Glo
luminescent viability assay (Promega) was used to measure cell viability seven days
after drug addition. Viability was calculated as the percentage of control (untreated
cells) after background subtraction with a minimum of three replicates for each cell
line/cDNA/drug concentration. GI50 values were determined as the drug dose
corresponding to half-maximal growth inhibition35; as such, the upper bound GI50
value in this assay is 680 nM. GI50 values for unmodified parental cells were
determined using the protocol above by seeding cells directly into 96-well plates
without the initial infection step.
Patient-derived xenograft. The first patient was diagnosed with stage IV
(metastatic) CRC in 2006. Surgical material derived from a second metastatic
relapse in the liver in 2009 was collected, cut into pieces and implanted in
NOD-SCID mice. Early passage specimens were used for this study. After
engraftment, the tumour was passaged and expanded for two generations until
production of four cohorts. These were randomized according to average
tumour size of 400mm3 and treated with vehicle alone (four mice), cetuximab
monotherapy (five mice), pimasertib monotherapy (four mice), or their
combination (five mice). The investigator was not blinded. Two mice, one in the
cetuximab arm and the other in the combo arm died during treatment for reasons
unrelated with pharmacological treatments and were therefore excluded from
subsequent analyses. Treatments started at the second week and lasted 6 weeks. At
this point, treatments were stopped and restarted after 6 weeks. Animals receiving
vehicle, or pimasertib alone had to be euthanized after 5 and 6 weeks of treatment
for ethical reasons. A second replicate of this PDX model was performed without
vehicle and pimasertib treated arms and without stopping the treatment with
cetuximab (six mice) or cetuximab plus pimasertib combination (eight mice). The
second patient was diagnosed with metastatic relapse from rectal cancer in 2008.
Surgical material derived from resection of a liver metastasis in 2009 was collected
under adequate informed consent, cut into pieces and implanted in NOD-SCID
mice. Early passage specimens were used also in this case. After engraftment, the
tumour was passaged and expanded for two generations until production of four
cohorts. These were randomized according to average tumour size of 400mm3 and
treated with vehicle alone (four mice), cetuximab monotherapy (six mice),
pimasertib monotherapy (five mice), or their combination (six mice). Caliper
measurements were taken once a week. Cetuximab was given by intraperitoneal
injection at 0.5mg kg 1 twice a week, and pimasertib was administered by gavage
at 50mg kg 1 per day. Pimasertib was resuspended in distilled sterile water
containing 0.5% carboxymethylcellulose (Sigma Aldrich) and 0.25% Tween 80
(Sigma Aldrich). All animal procedures were approved by the Ethical Commission
of the Institute for Cancer Research and Treatment and by the Italian Ministry of
Health. Informed consent for research use of patient tumour material was obtained
from patients at the Candiolo Cancer Institute prior to tissue banking and study
approval was obtained from the ethics committee of the enroling institution.
Immunohystochemical analyses. Xenografts were embedded in paraffin and
subjected to hematoxylin-and-eosin staining or to immunoperoxidase staining with
the mouse monoclonal anti-Ki-67 antibody (clone MIB-1, Dako). After incubation
with secondary antibodies, immunoreactivities were revealed by incubation in DAB
chromogen (Dako). Images were captured with the Leica LAS EZ software using a
Leica DM LB microscope.
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